您的位置: 首页 > 2018年7月 第49卷 第4期 > 文字全文
2023年7月 第38卷 第7期11
目录

社区综合防治合作模式对基层高血压病患者的药物经济学评价

Pharmacoeconomic evaluation of community comprehensive prevention on the pharmacotherapy of hypertension in grassroots community

来源期刊: 广州医药 | 24-29 发布时间:2021-11-29 收稿时间:2025/11/13 17:20:00 阅读量:46
作者:
关键词:
社区综合防治模式高血压药物经济学
Comprehensive intervention in communityHypertensionPharmacoeconomics
DOI:
10.3969/j.issn.1000-8535.2018.04.007
收稿时间:
2018-03-24 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 观察社区综合防治健康管理模式对社区高血压患者血压控制疗效及药物经济学的影响。方法 收集2012年7月—2013年7月广州参与研究的三级医院及社区卫生服务中心收治的原发性高血压病患者2 383例,病例入组后随机分为综合管理组和常规治疗组。记录及随访两组高血压患者基线血压值、降压药物使用方案、是否更换药物、血压控制疗效及药物经济学相关费用情况。结果 与常规治疗组相比,综合管理组患者血压治疗效果较好,显效率及总有效率提高[(60.71% vs 46.01%); (90.20% vs 71.06%), P<0.001];高血压治疗及管理的药物费用虽有升高(t=16.186,P<0.001),但相关的门诊费用、住院费用、护理费用及总费用降低(t=25.647, t=35.785, t=22.274,t=73.710,P<0.001);在降压方案方面,从减少抗高血压药物使用,减少费用考虑,单独用药方式适合单纯性轻度高血压患者,从费用效果分析上,成本效果比以单药组最低,联用药组逐渐增大;增量成本-效果比:二药联用降压方案优于其他降压联合方案,因而两药联用降压为兼顾疗效和成本的降压较佳组合。结论 应用社区综合防治模式对高血压患者进行干预,效果满意,能够有效降低成本-效果比,值得临床推广应用。
Objective To investigate the effects of comprehensive prevention and control measures on the therapeutic efficient and pharmacoeconomics in community hypertension patients. Methods 2383 cases of hypertension were collected from July 2012 to July 2013 in the tertiary and community hospitals in Guangzhou, which were randomly divided into general therapy group, in which the patients were treated by general administration of drugs, and comprehensive management group that the patients were visited regularly. The sources of drugs, drugs use and changes in drugs were investigated. Results Compared with the general therapy group, better treatment effects were achieved in the comprehensive group. The apparent efficiency and total efficiency were both increased in the comprehensive group[(60.71% vs 46.01%); (90.20% vs 71.06%), P<0.001]. Although the therapy and pharmacy fees were slightly increased in the comprehensive group as compared to the control group (t=16.186, P<0.001), the outpatient expenses,hospitalization expenses, nursing expenses and the total expenses were decreased(t=25.647; t=35.785; t=22.274;t=73.710;P<0.001). Considering reducing the use of drugs and decreasing the cost, the method of using single drug is beneficial to the patients of low-risk mild hypertension. The method of using calcium antagonist is the most economical and reasonable way. Conclusion Standardizing management of hypertension in community is effective in improving hypertension treatment and decreasing the cost, which is thus worth popularizing.
1、 LOGAN A G, IRVINE M J, MCISAAC W J,et al.Effect of home blood pressure telemonitoring with self-care support on uncontrolled systolic hypertension in diabetics[J]. Hypertension,2012,60(1):51-57. LOGAN A G, IRVINE M J, MCISAAC W J,et al.Effect of home blood pressure telemonitoring with self-care support on uncontrolled systolic hypertension in diabetics[J]. Hypertension,2012,60(1):51-57.
2、 WANG X, LI W, LI X, et al. Effects and cost-effectiveness of a guideline-oriented primary healthcare hypertension management program in Beijing, China: results from a 1-year controlled tria[J]. Hypertens Res, 2013, 36(4):313-321. WANG X, LI W, LI X, et al. Effects and cost-effectiveness of a guideline-oriented primary healthcare hypertension management program in Beijing, China: results from a 1-year controlled tria[J]. Hypertens Res, 2013, 36(4):313-321.
3、 CLAUDE L, CHOBANIAN A V, JONES D W, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure[J]. Hypertension, 2003,42(6):1206-1252. CLAUDE L, CHOBANIAN A V, JONES D W, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure[J]. Hypertension, 2003,42(6):1206-1252.
4、 MOREIRA G C, CIPULLO J P, MARTIN J F V, et al. Evaluations of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study[J]. J Hypertens, 2009, 27(9):1900-1907. MOREIRA G C, CIPULLO J P, MARTIN J F V, et al. Evaluations of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study[J]. J Hypertens, 2009, 27(9):1900-1907.
5、 GEROY L S A. Economic evaluation for first-line anti-hypertensive medicines: applications for the Philippines[J]. Cost Eff Resour Allocat, 2012, 10 (1):1-10. GEROY L S A. Economic evaluation for first-line anti-hypertensive medicines: applications for the Philippines[J]. Cost Eff Resour Allocat, 2012, 10 (1):1-10.
6、 WANG Z W, WANG X, CHEN Z, et al. Hypertension control in community health centers across China: analysis of antihypertensive drug treatment patterns[J]. J Hypertens, 2014, 27 (2):252-259. WANG Z W, WANG X, CHEN Z, et al. Hypertension control in community health centers across China: analysis of antihypertensive drug treatment patterns[J]. J Hypertens, 2014, 27 (2):252-259.
7、 冯芮华,王增武,王小万,等.高血压社区规范化管理中常用抗高血压药物的成本-效果研究[J]. 中国全科医学,2016,19(1):92-95. 冯芮华,王增武,王小万,等.高血压社区规范化管理中常用抗高血压药物的成本-效果研究[J]. 中国全科医学,2016,19(1):92-95.
8、 WANG Y, WANG Y, GU H, et al. Use of home blood pressure monitoring among hypertensive adults in primary care: Minhang community survey[J]. Blood Press Monit, 2014,19(3):140-144. WANG Y, WANG Y, GU H, et al. Use of home blood pressure monitoring among hypertensive adults in primary care: Minhang community survey[J]. Blood Press Monit, 2014,19(3):140-144.
9、 KAZUAKI S, KATSUYUK A, TOSHIRO F, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014)[J]. Hypertens Res, 2014, 37(4):291-300. KAZUAKI S, KATSUYUK A, TOSHIRO F, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014)[J]. Hypertens Res, 2014, 37(4):291-300.
10、 MANCIA G, FAGARD R, NARKIEWICZ K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension; the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. J Hypertens, 2013, 31(7):1281-1357. MANCIA G, FAGARD R, NARKIEWICZ K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension; the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. J Hypertens, 2013, 31(7):1281-1357.
11、 黄冠又,张欣,明悦,等.174例高血压基底节脑出血内科治疗及预后因素分析[J]. 广州医药, 2016, 47(5): 23-25. 黄冠又,张欣,明悦,等.174例高血压基底节脑出血内科治疗及预后因素分析[J]. 广州医药, 2016, 47(5): 23-25.
12、 向海卿,崔莉,李梁,等. 清远连南瑶族自治县农村居民高血压患病率及知晓情况调查[J]. 现代医院,2017, 17(9): 1318-1320. 向海卿,崔莉,李梁,等. 清远连南瑶族自治县农村居民高血压患病率及知晓情况调查[J]. 现代医院,2017, 17(9): 1318-1320.
13、 《中国高血压基层管理指南》修订委员会.中国高血压基层管理指南(2014年修订版)[J]. 中华高血压杂志,2015,23(1):24-43. 《中国高血压基层管理指南》修订委员会.中国高血压基层管理指南(2014年修订版)[J]. 中华高血压杂志,2015,23(1):24-43.
14、 国家卫生和计划生育委员会. 中国卫生和计划生育统计年鉴2015[M]. 北京:中国协和医科大学出版社,2016. 国家卫生和计划生育委员会. 中国卫生和计划生育统计年鉴2015[M]. 北京:中国协和医科大学出版社,2016.
15、 国家心血管病中心. 中国心血管病报告2016[M]. 北京: 中国大百科全书出版社, 2017. 国家心血管病中心. 中国心血管病报告2016[M]. 北京: 中国大百科全书出版社, 2017.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录